These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21240332)

  • 1. [Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
    Acuña C
    Drugs Today (Barc); 2010 Dec; 46 Suppl F():1-12. PubMed ID: 21240332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
    Matthaei S
    MMW Fortschr Med; 2009 Oct; 151(42):54. PubMed ID: 19938786
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
    Seck TL; Engel SS; Williams-Herman DE; Sisk CM; Golm GT; Wang H; Kaufman KD; Goldstein BJ
    Diabetes Res Clin Pract; 2011 Jul; 93(1):e15-7. PubMed ID: 21477878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
    Perusicová J
    Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sitagliptin for Type 2 diabetes: a 2015 update.
    Lee M; Rhee MK
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):597-610. PubMed ID: 26000559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
    Mori Y; Taniguchi Y; Matsuura K; Sezaki K; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2011 Jul; 13(7):699-703. PubMed ID: 21504334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.
    Neumiller JJ; Odegard PS; White JR; Setter SM; Campbell RK
    Diabetes Educ; 2008; 34(2):183-200. PubMed ID: 18375772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
    Rabasseda X
    Drugs Today (Barc); 2011 Nov; 47 Suppl D():1-8. PubMed ID: 22439134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin: a review.
    Subbarayan S; Kipnes M
    Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?
    de Oliveira JM
    BMJ; 2013 Jun; 346():f3568. PubMed ID: 23737277
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 19. [Combination antidiabetic therapy. Better control of blood glucose values].
    Bischoff A
    MMW Fortschr Med; 2009 Oct; 151(42):55. PubMed ID: 19938787
    [No Abstract]   [Full Text] [Related]  

  • 20. Sitagliptin: a viewpoint by Mark S. Kipnes.
    Kipnes MS
    Drugs; 2007; 67(4):598-9. PubMed ID: 17352517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.